Tetsuya Takimoto
Overview
Explore the profile of Tetsuya Takimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sekimizu M, Watanabe T, Fukushima H, Koh K, Yuza Y, Takeshima Y, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31590.
PMID: 39948694
Background: Localized lymphoblastic lymphoma (LL) is rare in pediatric patients. The best treatment for patients with localized LL remains to be determined because of the rarity of the disease. Methods:...
2.
Kato Y, Inaba T, Shinke K, Hiramatsu N, Horie T, Sakamoto T, et al.
Cells
. 2025 Feb;
14(3).
PMID: 39937006
Developmental toxicity testing is essential to identify substances that may harm embryonic development. This study aimed to establish a protocol for evaluating developmental toxicity using human induced pluripotent stem cells...
3.
Kato Y, Seishima R, Hattori K, Kato H, Ishida H, Shigeta K, et al.
Br J Cancer
. 2025 Feb;
PMID: 39934338
Background: Colorectal cancer (CRC) is a substantial global health concern due to its limited treatment options, especially for oxaliplatin (L-OHP) regimen resistance. This study used organoid-based screening methodologies to evaluate...
4.
Chikaishi Y, Matsuoka H, Sugihara E, Takeda M, Sumitomo M, Yamada S, et al.
Cancer Sci
. 2025 Jan;
PMID: 39822019
Colorectal cancer (CRC) is well characterized in terms of genetic mutations and the mechanisms by which they contribute to carcinogenesis. Mutations in APC, TP53, and KRAS are common in CRC,...
5.
Hosoi H, Miyachi M, Teramukai S, Sakabayashi S, Tsuchiya K, Kuwahara Y, et al.
Int J Clin Oncol
. 2024 Aug;
29(11):1746-1755.
PMID: 39177879
Background: Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m. However, this dose may...
6.
Saeki I, Ida K, Kurihara S, Watanabe K, Mori M, Hishiki T, et al.
Pediatr Blood Cancer
. 2024 Aug;
71(11):e31255.
PMID: 39126361
Background: The JPLT3-S (Japanese Study Group for Pediatric Liver Tumors-3) study, conducted cisplatin (CDDP) monotherapy for young children (<3 years old) with standard-risk hepatoblastoma (HB) using a central review system...
7.
Salzman M, Takimoto T, Foster M, Mowat F
Exp Eye Res
. 2024 Jun;
245:109980.
PMID: 38914302
The dog retina contains a central macula-like region, and there are reports of central retinal disorders in dogs with shared genetic etiologies with humans. Defining central/peripheral gene expression profiles may...
8.
Ishida H, Imamura T, Kobayashi R, Hashii Y, Deguchi T, Miyamura T, et al.
Cancer Med
. 2024 Jun;
13(12):e7246.
PMID: 38888368
Background: Asparaginase is essential for treating T-cell acute lymphoblastic leukemia (T-ALL). Despite the ongoing debate on whether T-ALL and T-cell lymphoblastic lymphoma (T-LBL) are the same disease entity or two...
9.
Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(6):e30976.
PMID: 38577760
Purpose: Survival rates of patients with high-risk neuroblastoma are unacceptable. A time-intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a...
10.
Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Fujisaki H, et al.
Biology (Basel)
. 2023 Oct;
12(10).
PMID: 37887060
High-risk neuroblastoma (HR-NB) patients remain far from obtaining optimal outcomes, with more than 50% relapse/regrowth rate despite current intensive multimodal therapy. This originated from the activation/proliferation of chemoresistant minimal residual...